Combination Treatment of Prostate Cancer Cell Lines with Bioactive Soy Isoflavones and Perifosine Causes Increased Growth Arrest and/or Apoptosis
Open Access
- 15 October 2007
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 13 (20), 6204-6216
- https://doi.org/10.1158/1078-0432.ccr-07-0600
Abstract
Purpose: To determine whether targeting the androgen receptor (AR) and Akt pathways using a combination of genistein combined polysaccharide (GCP) and perifosine is more effective at inducing growth arrest/apoptosis in prostate cancer cells compared with treatment with GCP or perifosine as single agents.Keywords
This publication has 37 references indexed in Scilit:
- GCP‐mediated growth inhibition and apoptosis of prostate cancer cells via androgen receptor‐dependent and ‐independent mechanismsThe Prostate, 2007
- A phase II study of perifosine (D-21226) in patients with previously untreated metastatic or locally advanced soft tissue sarcoma: A National Cancer Institute of Canada Clinical Trials Group trialInvestigational New Drugs, 2006
- Enhancement of antitumor activity of the anti-EGF receptor monoclonal antibody cetuximab/C225 by perifosine in PTEN-deficient cancer cellsOncogene, 2005
- Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferationEndocrine-Related Cancer, 2005
- In vitro Combination Treatment with Perifosine and UCN-01 Demonstrates Synergism against Prostate (PC-3) and Lung (A549) Epithelial Adenocarcinoma Cell LinesClinical Cancer Research, 2004
- A Concentrated Aglycone Isoflavone Preparation (GCP) That Demonstrates Potent Anti-Prostate Cancer Activity In vitro and In vivo Clinical Cancer Research, 2004
- Molecular alterations associated with LNCaP cell progression to androgen independenceThe Prostate, 2004
- Molecular determinants of resistance to antiandrogen therapyNature Medicine, 2003
- Isoflavone Aglycon Produced by Culture of Soybean Extracts with Basidiomycetes and Its Anti-angiogenic ActivityBioscience, Biotechnology, and Biochemistry, 2002
- VARIOUS FORMS OF MUTANT p53 CONFER SENSITIVITY TO CISPLATIN AND DOXORUBICIN IN BLADDER CANCER CELLSJournal of Urology, 2001